Outcomes

MM Matthew Moll
PS Phuwanat Sakornsakolpat
NS Nick Shrine
BH Brian D Hobbs
DD Dawn L DeMeo
CJ Catherine John
AG Anna L Guyatt
MM Michael J McGeachie
SG Sina A Gharib
MO Ma'en Obeidat
LL Lies Lahousse
SW Sara R A Wijnant
GB Guy Brusselle
DM Deborah A Meyers
EB Eugene R Bleecker
XL Xingnan Li
RT Ruth Tal-Singer
AM Ani Manichaikul
SR Stephen S Rich
SW Sungho Won
WK Woo Jin Kim
AD Ah Ra Do
GW George R Washko
RB R Graham Barr
BP Bruce M Psaty
TB Traci M Bartz
NH Nadia N Hansel
KB Kathleen Barnes
JH John E Hokanson
JC James D Crapo
DL David Lynch
PB Per Bakke
AG Amund Gulsvik
IH Ian P Hall
LW Louise Wain
SW Scott T Weiss
ES Edwin K Silverman
FD Frank Dudbridge
MT Martin D Tobin
MC Michael H Cho
request Request a Protocol
ask Ask a question
Favorite

The primary outcome measure was moderate-to-severe COPD (FEV1/FVC <0·7 and FEV1 <80% of predicted). As secondary outcome measures, we assessed the association of the combined polygenic risk score with smoking, occurrence of exacerbations, GOLD spirometry grades, clinical COPD phenotypes, imaging phenotypes, and lung growth patterns. We also assessed the performance of the polygenic risk scores (alone and in combination with clinical COPD risk factors) in predicting COPD, and compared this with the performance of a clinical risk score.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A